Fat Burner Research Center
Thermogenics, Metabolism &
Fat Loss Science
Objective, evidence-graded analysis of fat burner ingredients. We separate genuine metabolic science from marketing mythology.
Mechanism: Stimulates sympathetic nervous system; increases norepinephrine release; enhances lipolysis and thermogenesis. Well-documented 3–11% increase in metabolic rate at clinical doses.
Mechanism: Inhibits catechol-O-methyltransferase (COMT), increasing norepinephrine. Synergistic with caffeine. Meta-analyses show modest body weight reductions (approximately 1–2 kg over 12 weeks).
Mechanism: Activates TRPV1 receptors; stimulates sympathetic nervous system; increases energy expenditure by 4–5%. Also shown to reduce ad libitum caloric intake in acute studies.
Mechanism: Beta-3 adrenergic receptor agonist; modest thermogenic effect. Often marketed as an ephedrine substitute. Evidence for fat loss is limited and cardiovascular concerns exist at higher doses.
Mechanism: Highly viscous soluble fiber that expands in the stomach, increasing satiety and delaying gastric emptying. EFSA has approved a health claim for glucomannan contributing to weight management.
Mechanism: Precursor to serotonin; may reduce carbohydrate cravings and caloric intake. Small human trials show promise but large-scale RCT data is lacking. Drug interactions are a significant concern.
Mechanism: Most satiating macronutrient per calorie. Increases PYY and GLP-1, reduces ghrelin, and has the highest thermic effect of food (25–30%). High protein diets consistently produce greater fat loss than isocaloric lower-protein diets.
Mechanism: AMPK activator with effects similar to metformin. Improves insulin sensitivity, reduces blood glucose, and may support fat loss—particularly in metabolically compromised individuals. Significant drug interactions exist.
Mechanism: Transports long-chain fatty acids into mitochondria for oxidation. Theoretically sound, but oral bioavailability is poor and studies in non-deficient individuals show minimal fat loss benefits at standard doses.
Mechanism: Modulates PPARs and may reduce fat storage while increasing fat oxidation. Meta-analyses show very modest reductions in body fat (~0.09 kg/week) in humans—far smaller than animal studies suggested.
Mechanism: Alpha-2 adrenergic receptor antagonist; may increase fat mobilization from adipose tissue, particularly in women. Significant side effects (anxiety, tachycardia) and drug interactions limit usefulness and safety.
Mechanism: Activates adenylyl cyclase, increasing cellular cAMP levels, which theoretically could increase lipolysis. Human trial evidence is extremely limited and of poor quality. Not recommended based on current evidence.
Banned by the FDA in 2004 following reports of cardiovascular events including heart attacks, strokes, and deaths. Despite demonstrated fat-loss efficacy, the risk-benefit ratio is unacceptable. Found in some grey-market products—avoid entirely.
Synthetic stimulant structurally similar to amphetamine. Associated with hemorrhagic stroke, cardiovascular events, and deaths. Banned by WADA and subject to FDA enforcement action. Still found in some supplements—check labels carefully.
An industrial chemical sometimes sold illegally as a weight-loss agent. Works by uncoupling oxidative phosphorylation, dramatically increasing metabolic rate—but has an extremely narrow margin between "dose" and lethal dose. Multiple deaths documented. Absolutely never use this compound under any circumstances.
Prescription appetite suppressant withdrawn from US, EU, and most markets in 2010 due to increased risk of cardiovascular events. Sibutramine contamination has been detected in numerous OTC weight-loss supplements by FDA testing—another reason to choose verified products carefully.
Quick Reference
Evidence Summary Table
A consolidated view of fat burner ingredients ranked by evidence quality and overall safety profile. Efficacy ratings reflect magnitude of real-world effect in human studies.
| Ingredient | Mechanism | Evidence Grade | Efficacy | Safety |
|---|---|---|---|---|
| Caffeine | Sympathomimetic / adenosine antagonist | A | High | Good (dose-dep.) |
| Protein (high intake) | Thermic effect / satiety hormones | A | High | Excellent |
| Green Tea (EGCG) | COMT inhibition / thermogenesis | B | Moderate | Good |
| Glucomannan | Viscous fiber / satiety | B | Moderate | Excellent |
| Capsaicin | TRPV1 activation / sympathomimetic | B | Moderate | Good |
| Berberine | AMPK activation | B | Moderate | Caution (interactions) |
| Synephrine | Beta-3 agonist | C | Low | Moderate concern |
| Yohimbine | Alpha-2 antagonist | C | Limited | Notable concerns |
| CLA | PPAR modulation | C | Weak | Good |
| L-Carnitine | Fatty acid transport | C | Weak | Excellent |
| 5-HTP | Serotonin precursor | C | Limited | Caution (interactions) |
| Forskolin | cAMP elevation | D | Insufficient | Unknown |